Baxter/Halozyme Hyaluronidase Enhanze SC Could See Approval By September
This article was originally published in The Pink Sheet Daily
The firms are touting the hyaluronidase agent’s recombinant human origin as a key advantage over currently available animal-derived hyaluronidase products. Enhanze SC would be the third hyaluronidase on the market but the first that is human-derived.
You may also be interested in...
Approval of Halozyme Therapeutics’ hyaluronidase product could be bogged down by ongoing legal arguments over Ista’s Vitrase exclusivity.
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.